1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015

Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015

Summary

GlobalData's clinical trial report, “Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015
Table of Contents
Introduction 6
Recurrent Malignant Glioma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Recurrent Malignant Glioma 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Recurrent Malignant Glioma Therapeutics Clinical Trials 31
Prominent Drugs 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
Merck and Co., Inc. 33
Clinical Trial Overview of Merck and Co., Inc. 33
INSYS Therapeutics, Inc. 34
Clinical Trial Overview of INSYS Therapeutics, Inc. 34
Eli Lilly and Company 35
Clinical Trial Overview of Eli Lilly and Company 35
Eisai Co., Ltd. 36
Clinical Trial Overview of Eisai Co., Ltd. 36
TransMolecular, Inc. 37
Clinical Trial Overview of TransMolecular, Inc. 37
Tactical Therapeutics, Inc 38
Clinical Trial Overview of Tactical Therapeutics, Inc 38
Shandong Lanjin Pharmaceuticals Co. Ltd 39
Clinical Trial Overview of Shandong Lanjin Pharmaceuticals Co. Ltd 39
Oncolytics Biotech Inc. 40
Clinical Trial Overview of Oncolytics Biotech Inc. 40
Amgen Inc. 41
Clinical Trial Overview of Amgen Inc. 41
Alkermes Plc 42
Clinical Trial Overview of Alkermes Plc 42
Clinical Trial Overview of Top Institutes / Government 43
National Cancer Institute 43
Clinical Trial Overview of National Cancer Institute 43
Duke University 45
Clinical Trial Overview of Duke University 45
Memorial Sloan Kettering Cancer Center 47
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 47
North American Brain Tumor Consortium 48
Clinical Trial Overview of North American Brain Tumor Consortium 48
University of Texas M. D. Anderson Cancer Center 49
Clinical Trial Overview of University of Texas M. D. Anderson Cancer Center 49
Northwestern University 50
Clinical Trial Overview of Northwestern University 50
UCLA's Jonsson Comprehensive Cancer Center 51
Clinical Trial Overview of UCLA's Jonsson Comprehensive Cancer Center 51
City of Hope 52
Clinical Trial Overview of City of Hope 52
University of Colorado 53
Clinical Trial Overview of University of Colorado 53
Five Key Clinical Profiles 54
Appendix 91
Abbreviations 91
Definitions 91
Research Methodology 92
Secondary Research 92
About GlobalData 93
Contact Us 93
Disclaimer 93
Source 93

List of Tables
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Region, 2015* 7
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Recurrent Malignant Glioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10
Recurrent Malignant Glioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Recurrent Malignant Glioma Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Recurrent Malignant Glioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Recurrent Malignant Glioma Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, G7 Countries (%), 2015* 15
Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, E7 Countries (%), 2015* 18
Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Recurrent Malignant Glioma Therapeutics, Global, Suspended Clinical Trials, 2015* 25
Recurrent Malignant Glioma Therapeutics, Global, Withdrawn Clinical Trials, 2015* 26
Recurrent Malignant Glioma Therapeutics, Global, Terminated Clinical Trials, 2015* 27
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28
Recurrent Malignant Glioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 29
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2015* 33
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by INSYS Therapeutics, Inc., 2015* 34
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2015* 35
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Co., Ltd., 2015* 36
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by TransMolecular, Inc., 2015* 37
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Tactical Therapeutics, Inc, 2015* 38
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Shandong Lanjin Pharmaceuticals Co. Ltd, 2015* 39
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Oncolytics Biotech Inc., 2015* 40
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2015* 41
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Alkermes Plc, 2015* 42
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 43
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2015* 45
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2015* 47
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by North American Brain Tumor Consortium, 2015* 48
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Texas M. D. Anderson Cancer Center, 2015* 49
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2015* 50
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by UCLA's Jonsson Comprehensive Cancer Center, 2015* 51
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by City of Hope, 2015* 52
Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Colorado, 2015* 53

List of Figures
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Recurrent Malignant Glioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 10
Recurrent Malignant Glioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Recurrent Malignant Glioma Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, G7 Countries (%), 2015* 15
Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, E7 Countries (%), 2015* 18
Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28
Recurrent Malignant Glioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 29
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
GlobalData Methodology 92

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Human Papillomavirus Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Human Papillomavirus Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • October 2016
  • by Global Data

Human Papillomavirus Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Human Papillomavirus Diagnostic Tests - Medical Devices Pipeline ...

Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • December 2016
  • by Global Data

Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, ...

Prostate Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Prostate Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • December 2016
  • by Global Data

Prostate Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Prostate Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.